{"bill":{"bill_id":1378963,"change_hash":"6eb2366e4594046981cbfd33e8d72b80","session_id":1658,"session":{"session_id":1658,"state_id":52,"year_start":2019,"year_end":2020,"prefile":0,"sine_die":1,"prior":1,"special":0,"session_tag":"Regular Session","session_title":"2019-2020 Regular Session","session_name":"116th Congress"},"url":"https:\/\/legiscan.com\/US\/bill\/HB8388\/2019","state_link":"https:\/\/www.congress.gov\/bill\/116th-congress\/house-bill\/8388\/all-info","completed":0,"status":1,"status_date":"2020-09-24","progress":[{"date":"2020-09-24","event":1},{"date":"2020-09-24","event":9}],"state":"US","state_id":52,"bill_number":"HB8388","bill_type":"B","bill_type_id":"1","body":"H","body_id":114,"current_body":"H","current_body_id":114,"title":"IMPROVE Addiction Care Act Improving Medicaid Programs' Response to Overdose Victims and Enhancing Addiction Care Act","description":"Establishes additional requirements for state Medicaid drug-use review programs with respect to individuals who experience opioid-related overdoses. Specifically, programs must include protocols that (1) connect individuals who have experienced an opioid-related overdose within the last five years to appropriate treatment; (2) notify providers who prescribe opioids about subsequent fatal overdoses; (3) ensure providers are notified about an individual's history of opioid-use disorder, overdoses, or poisonings; and (4) educate providers about proper prescribing practices for these individuals.","pending_committee_id":2302,"committee":{"committee_id":2302,"chamber":"H","chamber_id":114,"name":"Energy And Commerce"},"referrals":[{"date":"2020-09-24","committee_id":2302,"chamber":"H","chamber_id":114,"name":"Energy And Commerce"}],"history":[{"date":"2020-09-24","action":"Introduced in House","chamber":"H","chamber_id":114,"importance":0},{"date":"2020-09-24","action":"Referred to the House Committee on Energy and Commerce.","chamber":"H","chamber_id":114,"importance":1}],"sponsors":[{"people_id":14903,"person_hash":"978ps3ad","party_id":"2","state_id":52,"party":"R","role_id":1,"role":"Rep","name":"Markwayne Mullin","first_name":"Markwayne","middle_name":"","last_name":"Mullin","suffix":"","nickname":"","district":"HD-OK-2","ftm_eid":12013169,"votesmart_id":135898,"opensecrets_id":"N00033410","knowwho_pid":378700,"ballotpedia":"Markwayne_Mullin","sponsor_type_id":1,"sponsor_order":1,"committee_sponsor":0,"committee_id":0,"state_federal":0},{"people_id":20101,"person_hash":"yceo15jf","party_id":"1","state_id":52,"party":"D","role_id":1,"role":"Rep","name":"Harley Rouda","first_name":"Harley","middle_name":"","last_name":"Rouda","suffix":"","nickname":"","district":"HD-CA-48","ftm_eid":43645647,"votesmart_id":179404,"opensecrets_id":"N00040666","knowwho_pid":617606,"ballotpedia":"Harley_Rouda","sponsor_type_id":2,"sponsor_order":2,"committee_sponsor":0,"committee_id":0,"state_federal":0}],"sasts":[{"type_id":1,"type":"Same As","sast_bill_number":"SB4702","sast_bill_id":1379013}],"subjects":[{"subject_id":13304,"subject_name":"Health"},{"subject_id":13593,"subject_name":"Drug safety, medical device, and laboratory regulation"},{"subject_id":13307,"subject_name":"Drug, alcohol, tobacco use"},{"subject_id":13208,"subject_name":"Health care quality"},{"subject_id":13210,"subject_name":"Health information and medical records"},{"subject_id":13239,"subject_name":"Medicaid"},{"subject_id":13490,"subject_name":"Prescription drugs"},{"subject_id":13285,"subject_name":"State and local government operations"}],"texts":[{"doc_id":2212749,"date":"2020-10-20","type":"Introduced","type_id":1,"mime":"application\/pdf","mime_id":2,"url":"https:\/\/legiscan.com\/US\/text\/HB8388\/id\/2212749","state_link":"https:\/\/www.congress.gov\/116\/bills\/hr8388\/BILLS-116hr8388ih.pdf","text_size":297278,"text_hash":"85074fc0ad719d307db9465e649dd4ee"}],"votes":[],"amendments":[],"supplements":[],"calendar":[]}}